ATLASATLAS fair value
CHF 22.64
Above fair value · 93% premium
Range: CHF 11–CHF 46Fair valuePrice
PolyPeptide (PPGN.SW)
PolyPeptide stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · SIX Swiss Exchange · Switzerland
CHF 43.80▲ 0.00%
Prices as of Oct 27, 2026 · CHF
Chance of rising in 1 month
52%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on PolyPeptide in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On PolyPeptide
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS estimates PolyPeptide's fair value at about CHF 22.64 per share (reasonable range: CHF 11.09 to CHF 45.76). At CHF 43.80, the stock trades 93% above it.
It is calculated with valuation multiples of comparable companies. Confidence in the estimate is low. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives PolyPeptide a 52% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between CHF 42.17 and CHF 45.80; in 9 out of 10, between CHF 39.19 and CHF 49.28. Estimated annual volatility is 3%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- CHF 1.5B
- Market cap (USD)
- $1.8B
- P/E ratio
- 107.4
- 52-week high
- CHF 50.10
- 52-week low
- CHF 21.80
- Revenue (12 months)
- €459M
- Gross margin
- 22.9%
- Operating margin
- 9.3%
- Net margin
- 3.2%
- Beta
- 0.97
What this means
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. PolyPeptide sits above fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks PPGN.SW has traded between CHF 21.80 and CHF 50.10. Today it is 12.6% below that high and 101% above its low.
On the business: net margin is 3.2%; it trades at 107.4 times earnings.
Its beta is 0.97: it moves roughly in line with the market.
About the company
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products.
Want to see everything about PolyPeptide?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What is PolyPeptide (PPGN.SW) fair value?
About CHF 22.64 per share according to ATLAS (reasonable range: CHF 11.09 to CHF 45.76). With the stock at CHF 43.80, it is 93% above it.
What is the chance PPGN.SW goes up next month?
52%: close to a coin flip. In half of the simulated outcomes, PPGN.SW ends the month between CHF 42.17 and CHF 45.80.
How big is PolyPeptide and what is its P/E ratio?
PolyPeptide's market capitalization is CHF 1.5B. Its price-to-earnings (P/E) ratio is 107.4: you pay CHF 107.4 for each CHF 1.00 of yearly earnings.
How volatile is PPGN.SW?
ATLAS estimates annual volatility at 3%. In a typical month, half of the outcomes end between CHF 42.17 and CHF 45.80.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer